← Eichor
Study identifier: NCT07377487 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

TheraSphere Japan Pre-Market Study

Condition: Liver Neoplasms  ·  Sponsor: Boston Scientific Corporation

PhaseNA
Planned participants51
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To investigate the safety and effectiveness of BSJ019T in Japanese patients with primary or secondary liver who are not candidate for standard treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Satoru Motohashi  ·  +81(80)4619-9640  ·  satoru.motohashi@bsci.com

Always discuss trial participation with your own doctor first.

Locations (4)

Hyogo College of Medicine HospitalNishinomiya, Hyōgo, JapanNot Yet Recruiting
Kanazawa University HospitalKanazawa, Ishikawa-ken, JapanRecruiting
Kindai University HospitalSayama, Osaka, JapanNot Yet Recruiting
National Cancer Center HospitalChuo Ku, Tokyo, JapanNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07377487